BrainsWay (BWAY) Q3 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2026 earnings summary
10 Nov, 2026Executive summary
Q3 systems shipped rose 44% YoY to 130, bringing the installed base to ~2,080; revenue grew 34% to $18.146m and RPO rose 31% to ~$85m.
Growth reflected Deep TMS adoption, recurring-revenue momentum and operating leverage; operating cash flow was $6.183m.
Financial highlights
Q3 revenue was $18.146m versus $13.512m; 9M revenue was $50.784m versus $37.680m.
Q3 gross profit was $14.135m versus $10.159m; gross margin was 78% versus 75% in Q3 2025 and Q2 2026.
Q3 operating income was $2.590m versus $1.253m; net income was $2.222m versus $1.566m.
Adjusted EBITDA was $3.873m versus $2.021m; margin expanded to 21% from 15%.
9M operating income was $6.986m versus $2.407m; net income was $7.222m versus $4.700m.
Outlook and guidance
FY26 revenue, operating-income margin and Adjusted EBITDA are expected at the upper end of prior guidance, with potential to modestly exceed it.
Management expects gross-margin improvement through year-end and operating income at the upper end of guidance.
2027 OpEx is expected to rise 15%-20%; further margin gains depend on book-to-bill remaining around 1.3x-1.4x.
Recurring revenue and RPO support visibility into growth and profitability into 2027.
Latest events from BrainsWay
- Revenue growth and rising profitability support an expanding Deep TMS platform.BWAY
Investor presentation - Deep TMS adoption accelerates globally, driving strong recurring revenue and rapid financial growth.BWAY
Investor presentation - Q2 2026 revenue up 35% YoY, margins and guidance raised, with strong cash flow and system growth.BWAY
Q2 2026 - Rapid ARR growth, clinical leadership, and global expansion drive strong financial momentum.BWAY
Investor presentation - Record revenue growth and profitability fueled by recurring revenue and clinical innovation.BWAY
Investor presentation - Q1 revenue up 35%, net income doubled, and record Deep TMS shipments drive strong outlook.BWAY
Q1 2026 - Record revenue and net income growth in 2025, with robust 2026 outlook and regulatory catalysts.BWAY
Q4 2025 - Record Q3 revenue, higher profits, raised guidance, and FDA clearance drive future growth.BWAY
Q3 2025 - 2024 revenue rose 29% to $41M, with 2025 growth guided at 20–24% and gross margin steady at 75%.BWAY
Q4 2024